ArticleBMC cancer2022
Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Ovarian carcinoid tumor with carcinoid heart syndrome: A case report and literature review.Gynecologic oncology reports · 2025Article
- Hypertension and Carcinoid Heart Disease as Initial Manifestations of Ovarian Carcinoid Tumor.JCEM case reports · 2025Article
- Case Report: Strumal carcinoid tumor in the ovary: report of a rare occurrence with a review of literature.Frontiers in medicine · 2025Article
- Clinicopathological and imaging features of struma ovarii: a retrospective study.Frontiers in oncology · 2025Article
- Diagnostic and therapeutic challenges of a rare large ovarian strumal carcinoid in pregnancy, about a case report.International journal of surgery case reports · 2024Article
- Incidental Diagnosis of a Primary Pure "Mixed" Ovarian Carcinoid: Clinicopathological Report and Concise Review of the Recent Series.Case reports in obstetrics and gynecology · 2024Article
- Neoplasms in Struma Ovarii: A Review.Endocrine pathology · 2023Review
- Incidence, clinical characteristics, and survival outcomes of ovarian strumal diseases: a retrospective cohort study.BMC women's health · 2023Article
- Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.Acta obstetricia et gynecologica Scandinavica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOvarian strumal carcinoid is an extremely rare ovarian malignant tumor with limited data on clinical characteristics and survival outcomes.
methodsA retrospective study of 119 patients was conducted, including 98 cases identified from literature review, and their clinical characteristics were investigated. The overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), and potential prognostic factors of these patients were also evaluated.
resultsLesions of 115 cases were confined to the ovarian while four patients presented with extra-ovarian disease upon initial diagnosis. Surgical treatment options performed in this cohort varied, 5.0% received ovarian cystectomy, 36.1% received unilateral salpingo-oophorectomy (USO), 7.6% received bilateral salpingo-oophorectomy (BSO), 42.0% received hysterectomy with BSO, and 8.4% underwent debulking surgery. Moreover, one patient did not undergo any surgery. No postoperative adjuvant therapy was administered in 89.9% patients, while 7.6% and 2.5% received adjuvant radiotherapy and chemotherapy, of which two patients received combined radiation and chemotherapy. At the final follow-up, 89.1% patients showed no evidence of the disease, and 5.0% were alive with the disease. Only seven deaths occurred, with two attributed to the tumor. The 5-year, 10-year, and 20-year OS rates were 96.0%, 85.0%, and 85.0%, respectively, with a 15-year recurrence rate of 4.4%. The 5-year and 20-year DSS rate were 98.5% and 95.9%. Multivariate Cox regression showed age ≥ 55 years was the only risk factor associated with the OS (P = 0.014, OR 7.988; 95% CI 1.519 - 42.004). However, the univariate and multivariate Cox regression showed no potential risk factor for RFS and DSS.
conclusionPatients with ovarian strumal carcinoid have an excellent prognosis irrespective of the surgical option. Conservative surgery especially USO with individualized adjuvant therapy is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.